KYMERA THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
KYMERA THERAPEUTICS, INC. (KYMR) reported Increase (Decrease) in Accounts Payable of $4.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$3.94M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $8.82M, a 125.27% increase year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.49M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$267.00K, a 390.22% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$1.97M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$307.00K, a 115.06% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $2.04M, a 705.53% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $253.00K, a 368.52% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.88M 10-Q · filed 2026-08-05 | $3.39M derived: sum of 3 quarters · filed 2026-08-05 | $3.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $8.82M 10-Q · filed 2026-04-30 | $7.33M derived: sum of 2 quarters · filed 2026-04-30 | $7.07M derived: sum of 3 quarters · filed 2026-04-30 | $2.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.76M derived: sum of 2 quarters · filed 2026-02-26 | -$5.89M derived: sum of 3 quarters · filed 2026-08-05 | -$1.97M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$267.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$4.40M derived: sum of 2 quarters · filed 2026-08-05 | -$483.00K 10-Q · filed 2025-11-04 | -$988.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$216.00K 10-Q · filed 2026-08-05 | -$721.00K derived: sum of 3 quarters · filed 2026-08-05 | -$629.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.92M 10-Q · filed 2026-04-30 | $3.41M derived: sum of 2 quarters · filed 2026-04-30 | $3.50M derived: sum of 3 quarters · filed 2026-04-30 | $3.54M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$505.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$413.00K derived: sum of 2 quarters · filed 2026-02-26 | -$382.00K derived: sum of 3 quarters · filed 2026-02-26 | -$307.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $123.00K derived: sum of 2 quarters · filed 2025-11-04 | $198.00K 10-Q · filed 2025-11-04 | $1.73M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $106.00K 10-Q · filed 2025-08-11 | $1.64M derived: sum of 3 quarters · filed 2026-02-26 | $2.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $75.00K 10-Q · filed 2025-05-09 | $1.61M derived: sum of 2 quarters · filed 2026-02-26 | $2.63M derived: sum of 3 quarters · filed 2026-02-26 | -$104.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.55M derived: sum of 2 quarters · filed 2026-02-26 | -$179.00K derived: sum of 3 quarters · filed 2026-02-26 | $2.04M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$1.71M derived: sum of 2 quarters · filed 2024-10-31 | $507.00K 10-Q · filed 2024-10-31 | -$1.56M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$513.00K 10-Q · filed 2024-08-07 | -$2.58M derived: sum of 3 quarters · filed 2025-02-27 | $1.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.22M 10-Q · filed 2024-05-02 | $149.00K derived: sum of 2 quarters · filed 2025-02-27 | $4.32M derived: sum of 3 quarters · filed 2025-02-27 | $3.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.10M derived: sum of 2 quarters · filed 2025-02-27 | $1.69M derived: sum of 3 quarters · filed 2025-02-27 | $253.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $4.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.76M derived: sum of 2 quarters · filed 2023-11-02 | $2.32M 10-Q · filed 2023-11-02 | $1.29M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$410.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.85M 10-Q · filed 2023-08-03 | -$2.88M derived: sum of 3 quarters · filed 2024-02-22 | -$5.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$1.44M 10-Q · filed 2023-05-04 | -$2.46M derived: sum of 2 quarters · filed 2024-02-22 | -$5.39M derived: sum of 3 quarters · filed 2024-02-22 | -$5.53M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$3.95M derived: sum of 2 quarters · filed 2024-02-22 | -$4.10M derived: sum of 3 quarters · filed 2024-02-22 | $54.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | -$2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.07M derived: sum of 2 quarters · filed 2022-11-03 | $1.08M 10-Q · filed 2022-11-03 | $1.55M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.00M 10-Q · filed 2022-08-09 | $4.47M derived: sum of 3 quarters · filed 2023-02-23 | $5.37M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $4.15M 10-Q · filed 2022-05-03 | $4.62M derived: sum of 2 quarters · filed 2023-02-23 | $5.51M derived: sum of 3 quarters · filed 2023-02-23 | $5.30M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.36M derived: sum of 2 quarters · filed 2023-02-23 | $1.15M derived: sum of 3 quarters · filed 2023-02-23 | $990.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $895.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $684.00K derived: sum of 2 quarters · filed 2021-11-10 | $523.00K 10-Q · filed 2021-11-10 | $1.93M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$372.00K 10-Q · filed 2021-08-06 | $1.03M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$161.00K 10-Q · filed 2021-05-06 | $1.25M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $904.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$503.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |